Lilly chalks up a win for Cymbalta in first U.S. trial over withdrawal symptom claims

Eli Lilly sfought off the first claims of withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta, as a federal jury found the drugmaker was not responsible for side effects such as brain zaps and suicidal thoughts in a patient who quit the med.

Lawyers for the plaintiff argued that Lilly downplayed serious withdrawal symptoms for Cymbalta by saying that the issues only affected a small percentage of patients who stopped taking it. But Lilly struck back, claiming that numbers weren’t relevant because some individuals quitting placebo also reported withdrawal symptoms, Bloomberg reports. And a psychiatrist who testified as an expert witness for the company said that the plaintiff’s symptoms could have been indicative of her underlying mental disorders…

Lilly is not the only drugmaker facing claims over withdrawal symptoms tied to antidepressants. GlaxoSmithKline ($GSK) is also encountering similar battles, with thousands of lawsuits alleging the drugmaker failed to warn patients about serious side effects including insomnia, headaches, dizziness and zapping sensations, tied to its antidepressant Paxil.

One thought on “Lilly chalks up a win for Cymbalta in first U.S. trial over withdrawal symptom claims

If you don't comment, I'll just assume you agree with me

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s